Alexion Pharmaceuticals, Inc. (ALXN) News

Alexion Pharmaceuticals, Inc. (ALXN): $158.06

2.77 (+1.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALXN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

Filter ALXN News Items

ALXN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALXN News Highlights

  • For ALXN, its 30 day story count is now at 24.
  • Over the past 22 days, the trend for ALXN's stories per day has been choppy and unclear. It has oscillated between 1 and 16.
  • The most mentioned tickers in articles about ALXN are ESQ, GNMK and MLND.

Latest ALXN News From Around the Web

Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.

Unknown Billionaire Phill Gross’ Top 10 Stock Picks

In the article, we discussed unknown billionaire Phil Gross’ top 10 stock picks and portfolio management strategy. Click to skip our discussion on Gross’ investment strategy and his latest portfolio updates to read Unknown Billionaire Phill Gross’ Top 5 Stock Picks. Adage Capital Management co-founder billionaire Phill Gross has successfully grown his money management firm […]

Yahoo | April 7, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates MLND, KSHB, GNMK, ALXN; Shareholders are Encouraged to Contact the Firm

NEW YORK, April 06, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Millendo Therapeutics, Inc. (NASDAQ: MLND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Tempest Therapeutics, Inc. Upon completion of the merger, Millendo shareholders are expected to own approximately 18.5% of the combined company while pre-merger Tempest stockholders will own approximately 81.5% of the combined company. If you are a Millendo shareholder, click here to learn more about your rights and options. KushCo Holdings, Inc. (OTCQX: KSHB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to ...

Yahoo | April 6, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds CATM, KTYB, ALXN and BFTL Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | April 6, 2021

ALERT: Halper Sadeh LLP Investigates the Following Mergers - FFG, SVBI, MX, ALXN, CATM, MDCA; Shareholders Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

Yahoo | March 30, 2021

SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

Yahoo | March 29, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds ENBL, ALXN, KTYB, and MDCA Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | March 26, 2021

Billionaire Paul Tudor Jones’ Top 10 Stock Picks and Latest Portfolio

In this article we presented billionaire Paul Tudor Jones’ top 10 stock picks. You can skip our detailed analysis of Jones’ investment strategy and his history to read Billionaire Paul Tudor Jones’ Top 5 Stock Picks. Paul Tudor Jones II is an American billionaire and hedge fund manager who founded Tudor Investment Corporation in 1980. […]

Yahoo | March 25, 2021

Orphan Drugs Market | Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international

Orphan Drugs Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players of

OpenPR | March 17, 2021

The FTC Is Taking a More Aggressive Approach Toward Pharmaceutical M&A. What It Means for the Industry.

The Federal Trade Commission warned it intends to take an aggressive approach to “anticompetitive pharmaceutical mergers." Analysts warn that biopharma deals could be harder to accomplish in the future.

Yahoo | March 17, 2021

AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt

AstraZeneca stock jumped Tuesday after the company reaffirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of its Covid vaccine.

Yahoo | March 16, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7069 seconds.